Moderna's US stock rose more than 6% before the market, after the company announced that the experimental influenza vaccine had reached the main end of the phase III clinical trial.

Zhitongcaijing · 06/30 11:17
Moderna's US stock rose more than 6% before the market, after the company announced that the experimental influenza vaccine had reached the main end of the phase III clinical trial.